Pure Global
NCT04944654

Efficacy, Tolerability and Acceptability of Biktarvy by TPLWH

Efficacy, Tolerability and Acceptability of the Single Table Regimen (STR) Biktarvy® by Trans People Living With HIV (TPLWH)
Chelsea and Westminster NHS Foundation Trust·Phase 4·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Human Immunodeficiency Virus
Drug/Device/Intervention
BIKTARVY 50Mg-200Mg-25Mg Tablet
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Chelsea and Westminster NHS Foundation Trust
Timeline & enrollment
Phase
Phase 4
Start date
Feb 01, 2022
End date
Oct 01, 2023
Enrollment
50 participants
Primary outcome

Measure of viral load

Summary

This is a clinical trial for TPLWH (Trans People Living with HIV) who are stable on cART with
 an undetectable viral load or a detectable viral load but no resistance to NRTIs and InSTI.
 Following written consent and screening procedures, study subjects will undergo a switch (or
 will restart) of their combination antiretroviral therapy (cART) to Biktarvy. The goal of
 this research project is to recruit an understudied population into a controlled clinical
 trial aimed at optimizing TPLWH cART. This will be demonstrated by measuring viral load
 outcomes at regular intervals, with a focus on viral load results 48 weeks after Biktarvy
 initiation (primary outcome).

ICD-10 classifications
Human immunodeficiency virus [HIV] diseaseUnspecified human immunodeficiency virus [HIV] diseaseHuman immunodeficiency virus [HIV] disease resulting in other conditionsHuman immunodeficiency virus [HIV] disease resulting in infectious and parasitic diseasesAsymptomatic human immunodeficiency virus [HIV] infection status
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT04944654
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT04944654 through Pure Global AI's free database. This Phase 4 trial is sponsored by Chelsea and Westminster NHS Foundation Trust and is currently Not yet recruiting. The study focuses on Human Immunodeficiency Virus. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.